Investing Ideas
/
Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth

Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

5 companies

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
867 China Medical System Holdings	HK$7.52	1.5%	-45.7%	HK$18.2b	HK$10.78	PE12.3x	E21.4%	5.5%
1530 3SBio	HK$5.93	-2.0%	-21.1%	HK$14.0b	HK$8.26	PE7.9x	E16.4%	4.0%
2186 Luye Pharma Group	HK$2.20	2.8%	-41.0%	HK$8.3b	HK$3.40	PE10.1x	E14.4%	0%
2877 China Shineway Pharmaceutical Group	HK$9.57	2.2%	31.6%	HK$7.2b	HK$12.88	PE6.2x	E8.1%	5.8%
1681 Consun Pharmaceutical Group	HK$7.80	0.1%	63.5%	HK$6.4b	HK$10.20	PE7.3x	E14.7%	7.4%

Page 1 of 1